June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date.Unlock Stocks

What Will Rite Aid-Walgreens Merger Mean To Fred's (FRED)?

Published 06/27/2017, 10:24 PM
Updated 07/09/2023, 06:31 AM
CVS
-
WBA
-
FREDQ
-
US90274J5618=UBSS
-

Shares of Fred's, Inc. (NASDAQ:FRED) , popularly known as Fred’s Pharmacy, rallied nearly 23% on Jun 26, on rumors about the Federal Trade Commission’s (FTC) approval of the much-awaited acquisition of Rite Aid Corporation (NYSE:RAD) by Walgreens Boots Alliance, Inc. (NASDAQ:WBA) . However, we await FTC’s final decision on the merger slated for Jul 7.

The possible nod of FTC on Rite Aid-Walgreens merger has also paved way for Fred’s. The company had inked a deal in Dec 2016 with Rite Aid and Walgreens to buy 865 stores located in the eastern and western U.S., along with certain assets for a total cash outlay of $950 million. Additionally, Fred’s Pharmacy announced that it might buy additional assets, including up to 1,200 Rite Aid stores, in order to obtain the FTC’s approval for the transaction.

How the Deal Would Benefit Fred?

The acquisition of these pharmacy stores is very crucial for Fred’s as it will place the company as the third largest drugstore chain in the U.S. after Walgreens and CVS Health Corporation (NYSE:CVS) . At present, the company operates 601 pharmacy and general merchandise outlets, along with three specialty pharmacy-only locations, comprising 14 franchised locations as of Jun 26, 2017. In addition, it possesses two distribution centers, each in Memphis, TN and Dublin, GA. The buyout of Rite Aid stores will more than double the company’s store count and would boost its network.

We note that Fred’s witnessed a slowdown in traffic in the last few quarters. This is evident from its sales that have been declining due to the fall in comparable store sales. Furthermore, the company has been reporting loss in the last four quarters.

In fact, the sluggishness is well reflected in the stock price performance of the company. Shares of Fred’s have declined over 14% in the past one year compared with the Zacks categorized Retail – Discount & Variety industry’s decline of 8.2%.



The deal is expected to aid this Zacks Rank #4 (Sell) company spark a turnaround. Additionally, the acquisitions will complement Fred’s strategy of focusing on the pharmacy department and contributing significantly to its overall performance. We believe that it will also improve the company’s healthcare growth strategy and would largely benefit its customers, patients, supplier partners and other stakeholders, going forward.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>



Fred's, Inc. (FRED): Free Stock Analysis Report

Rite Aid Corporation (RAD): Free Stock Analysis Report

CVS Health Corporation (CVS): Free Stock Analysis Report

Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.